Successfully conducted E&Y cGMP audit in May 2018.    2D barcode printing on all products implemented from May 2018.   Received ISO 9001:2015 Certification in July 2018.   Received ISO 14001:2015 Certification in December 2019.   Received ISO 45001:2018 Certification in December 2020.

Ceftro® Injection 250mg IV

Ceftriaxone is a semi-synthetic, 3rd-generation cephalosporin antibiotic, with the high degree of stability to B-lactamases, broad-spectral activity, and the effectiveness and convenience of long action.

Ceftro 250 MG

Ceftro 250 MG
Ceftro 250 MG
  • Dosage and Administration

    Ceftriaxone may be administered intravenously or intramuscularly. Ceftriaxone for injection should be administered intravenously by infusion over a period of 30 minutes.
    Adults: The usual adult daily dose is 1 to 2 grams given once a day (or in equally divided doses twice a day) depending on the type and severity of infection. For infections caused by Staphylococcus aureus (MSSA), the recommended daily dose is 2 to 4 grams, in order to achieve >90% target attainment. The total daily dose should not exceed 4 grams. If Chlamydia trachomatis is a suspected pathogen, appropriate antichlamydial coverage should be added, because ceftriaxone sodium has no activity against this organism. For preoperative use (surgical prophylaxis), a single dose of 1 gram administered intravenously 1/2 to 2 hours before surgery is recommended. Generally, ceftriaxone therapy should be continued for at least 2 days after the signs and symptoms of infection have disappeared. The usual duration of therapy is 4 to 14 days; in complicated infections, longer therapy may be required. When treating infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days. No dosage adjustment is necessary for patients with impairment of renal or hepatic function. Pediatric Patients: For the treatment of skin and skin structure infections, the recommended total daily dose is 50 to 75 mg/kg given once a day (or in equally divided doses twice a day). The total daily dose should not exceed 2 grams. For the treatment of serious miscellaneous infections other than meningitis, the recommended total daily dose is 50 to 75 mg/kg, given in divided doses every 12 hours. The total daily dose should not exceed 2 grams. In the treatment of meningitis, it is recommended that the initial therapeutic dose be 100 mg/kg (not to exceed 4 grams). Thereafter, a total daily dose of 100 mg/kg/day (not to exceed 4 grams daily) is recommended. The daily dose may be administered once a day (or in equally divided doses every 12 hours). The usual duration of therapy is 7 to 14 days. Neonates: Hyperbilirubinemic neonates, especially prematures, should not be treated with ceftriaxone for injection. Ceftriaxone is contraindicated in neonates if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium

Product Leaflet

Ceftro-Insert-1